GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2007

CytoDyn Selects Waisman Facility to Manufacture DNA-based Preflu Vaccine

  • CytoDyn chose the Waisman Clinical BioManufacturing Facility at the University of Wisconsin at Madison to manufacture its DNA-based preflu vaccine. The company says the product provides an alternative approach to immunization that could make flu vaccines for the seasonal flu and bird flu more effective.

    The vaccine uses DNA technology to implant a false memory of previous exposure to the flu virus, including the inactivated virus contained in standard vaccines.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?